GABRR3: A Potential Drug Target for Psychiatric Disorders (G200959)

Target Name: GABRR3

NCBI ID: G200959

GABRR3

GABRR3: A Potential Drug Target for Psychiatric Disorders

GABRR3 (Gamma-Aminobutyric Acid Type A Receptor Rho3 Subunit) is a protein that is expressed in many different tissues throughout the body. It is a subunit of the GABA-Aminobutyric Acid (GABA) receptor, which is a well-known neurotransmitter that plays a crucial role in the regulation of neural activity. GABRR3 is a potential drug target or biomarker for a variety of neurological and psychiatric disorders.

The GABA receptor is a type of ion channel that is expressed in the brain and other nervous tissue. It is composed of a subunit that is called GABA-R, which consists of a transmembrane protein and a cytoplasmic protein called GABA-Z. The GABA-R subunit is composed of four domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a catalytic domain. The GABA-R subunit is responsible for transmitting signals from the brain to other parts of the body, particularly the muscles and the nervous system.

GABRR3 is a single gene that encodes the GABA-R subunit. It is a member of the superfamily of GABA-R-like proteins, which are characterized by the presence of a conserved domain that is similar to that of GABA-R. GABRR3 is expressed in many different tissues throughout the body, including the brain, heart, pancreas, and skin.

GABRR3 has been shown to play a role in the regulation of a variety of physiological processes. For example, GABRR3 has been shown to be involved in the regulation of muscle contractions, and it has been shown to play a role in the regulation of pain perception. It has also been shown to be involved in the regulation of neurotransmitter release, and in the modulation of neurotransmitter signaling.

GABRR3 has also been shown to be involved in the development and progression of a variety of psychiatric and neurological disorders. For example, GABRR3 has been shown to be involved in the development of Alzheimer's disease, and it has been shown to play a role in the treatment of depression and anxiety disorders. It has also been shown to be involved in the regulation of brain function in individuals with ADHD, and in the modulation of brain activity in individuals with schizophrenia.

GABRR3 is a potential drug target or biomarker for a variety of psychiatric and neurological disorders. For example, GABRR3 has been shown to be involved in the regulation of neurotransmitter release, and it has been shown to play a role in the treatment of depression and anxiety disorders. It is also thought to be involved in the regulation of pain perception, and it has been shown to have potential as a pain treatment agent. Additionally, GABRR3 may be a target for neurodegenerative diseases, such as Alzheimer's disease, due to its involvement in the regulation of neurotransmitter release and its expression in the brain.

In conclusion, GABRR3 is a protein that is expressed in many different tissues throughout the body and is involved in the regulation of a variety of physiological processes. It is a potential drug target or biomarker for a variety of psychiatric and neurological disorders, including Alzheimer's disease, depression, anxiety, and pain. Further research is needed to fully understand the role of GABRR3 in the regulation of neural activity and the development and progression of psychiatric and neurological disorders.

Protein Name: Gamma-aminobutyric Acid Type A Receptor Subunit Rho3

Functions: GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

The "GABRR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GABRR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets